Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatitis C

Hepatitis C

Part of Hepatitis

21 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatitis C

319 trials tracked for Hepatitis C: 128 in phase 3 or 4 and 55 with published results. The most-cited published study has 1126 citations.

319Trials tracked
128Phase 3 & 4
0Recruiting
55With published results
Phase distribution
Phase 4 32 Phase 3 96 Phase 2 98 Phase 1 29 Other / NA 64
  1. Phase 4 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Completed · 1,126 cited
  2. Phase 3 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection Completed · 1,117 cited
  3. Phase 3 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Completed · 853 cited
  4. Phase 3 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection Completed · 851 cited
  5. Phase 3 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis Completed · 809 cited
  6. Phase 3 Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) Completed · 670 cited
Show 44 more trials
  1. Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy Completed · 566 cited
  2. Phase 3 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor Completed · 566 cited
  3. Phase 3 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection Completed · 469 cited
  4. Phase 4 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Completed · 313 cited
  5. Phase 3 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Completed · 305 cited
  6. Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 296 cited
  7. Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 278 cited
  8. Phase 3 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy Completed · 239 cited
  9. Phase 3 Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis Completed · 239 cited
  10. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Completed · 231 cited
  11. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy Completed · 203 cited
  12. Phase 3 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Completed · 189 cited
  13. Phase 3 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) Completed · 182 cited
  14. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection Completed · 161 cited
  15. Phase 3 Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Completed · 151 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Completed · 147 cited
  17. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV Completed · 120 cited
  18. Phase 3 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection Completed · 118 cited
  19. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection Completed · 113 cited
  20. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection Completed · 113 cited
  21. Phase 4 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Completed · 109 cited
  22. Phase 3 Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) Completed · 77 cited
  23. Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) Completed · 75 cited
  24. Phase 3 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Completed · 74 cited
  25. Phase 3 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) Completed · 54 cited
  26. Phase 3 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Completed · 53 cited
  27. Phase 3 A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Completed · 50 cited
  28. Phase 4 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors Completed · 49 cited
  29. Phase 3 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Completed · 49 cited
  30. Phase 3 Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. Completed · 49 cited
  31. Phase 3 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) Completed · 46 cited
  32. Phase 3 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Completed · 43 cited
  33. Phase 3 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV Completed · 43 cited
  34. Phase 4 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds Completed · 42 cited
  35. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Completed · 39 cited
  36. Phase 3 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Completed · 39 cited
  37. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis Completed · 39 cited
  38. Phase 3 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) Completed · 39 cited
  39. Phase 4 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed · 34 cited
  40. Phase 4 Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis Completed · 27 cited
  41. Phase 4 Multi-center Study to Transplant Hepatitis-C Infected Kidneys Completed · 20 cited
  42. Phase 3 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection Completed · 15 cited
  43. Phase 3 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis Completed · 15 cited
  44. Phase 3 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection Completed · 15 cited

Showing the 50 most-cited and recently-updated of 319 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hepatitis C: what the trials found

Sofosbuvir-based regimens demonstrate high efficacy in treating Hepatitis C. Specifically, sofosbuvir/velpatasvir (SOF/VEL) achieved a 95% SVR12 rate with low rates of serious adverse events (3.5%) and unplanned clinic visits (3.8%) 6. Other trials confirmed the use of sofosbuvir/velpatasvir in various settings, including post-transplant contexts where it showed specific outcomes regarding allograft rejection and graft loss 1, as well as general treatment cohorts [16, 17].

Alternative regimens such as glecaprevir/pibrentasvir demonstrated high viral response rates at 2 and 4 weeks with no Grade 3 or higher treatment-related adverse events reported 20. Additionally, glecaprevir/pibrentasir showed a 12% on-treatment virologic failure rate but 0% post-treatment virologic relapse 11.

The use of Zepatier (elbasvir/grazoprevir) was evaluated across multiple studies; it showed no Grade 3 or higher treatment-related adverse events and stable kidney function at 6 and 12 months [5, 13, 15]. Other combinations including elbasvir/grazoprevir were also utilized in post-transplant settings 14 and as EBR/GZR 21.

Harvoni (ledipasvir/sofosbuvir) was associated with a statistically significant reduction in liver fibrosis 19, and significantly higher rates of ALT normalization compared to other sofosbuvir-based DAA therapies 19. Other interventions included ribavirin 9, antiretroviral therapy (ART) 8, and TDF with a boosted protease inhibitor, the latter of which showed specific changes in PBMC levels and renal biomarkers 18.

Recent results — preliminary, needs further review

  • Mobile Enhanced Prevention Support significantly increased the number of participants who initiated a PrEP regimen compared to those who did not (p=0.0006) 2.
  • Maraviroc showed no significant change in Hepatitis C viral load at 4 weeks or 7 days post-initiation 12.

For the clinician treating this condition

  • Sofosbuvir/velpatasvir is a highly effective treatment with high SVR12 rates and manageable safety profiles [6, 16, 17].
  • Harvoni (ledipasvir/sofosbuvir) is associated with significant improvements in liver fibrosis and ALT normalization 19.
  • Glecaprevir/pibrentasvir shows high early viral response rates and favorable safety profiles [11, 20].
  • Zepatier (elbasvir/grazoprevir) demonstrates a favorable safety profile regarding renal function and severe adverse events [5, 13, 15].

AI synthesis of 12 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV
Oncology Meta-analysis
Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV Direct-acting antivirals show promise for patients with liver cancer
This meta-analysis of 8,839 patients with hepatocellular carcinoma (HCC) and Hepatitis C virus infection found that direct-acting antivirals…
New data suggests that direct-acting antiviral drugs may improve survival and reduce cancer recurrence for people with Hepatitis C and liver…
Jul 15, 2026
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations
Drug Pipeline Sys. Review
HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations HLA genes shape HIV and hepatitis vaccine responses and drug reactions
This narrative review examines HLA polymorphisms in HIV, hepatitis C, and hepatitis B. The clearest preventive paradigm is HLA-B*57:01-guide…
A review finds that HLA genes strongly influence how people respond to HIV and hepatitis vaccines and how they react to certain medications.
Frontiers Jun 6, 2026
Chronic HCV infection drives T cell dysfunction, regulatory T cell accumulation, and metabolic defects that persist after viral clearance
Allergy & Immunology Sys. Review
Chronic HCV infection drives T cell dysfunction, regulatory T cell accumulation, and metabolic defects that persist after viral clearance Immune defects in hepatitis C may last after the virus is gone
This narrative review examines immune mechanisms in patients with chronic hepatitis C virus infection. The authors describe how prolonged an…
A review explains how chronic hepatitis C causes lasting immune changes that persist even after the virus is cleared, suggesting new treatme…
Frontiers Jun 1, 2026
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds
Infectious Disease Meta-analysis
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds 1 in 6 blood donors in Cameroon carries malaria parasite
A systematic review and meta-analysis of 18 studies (~12,500 donations) found a 16.6% pooled prevalence of Plasmodium spp. in Cameroonian bl…
A review of 18 studies finds 16.6% of blood donations in Cameroon contain Plasmodium, the malaria parasite.
May 30, 2026
Narrative review on ICIs in patients with viral infections and solid tumors
Allergy & Immunology Sys. Review
Narrative review on ICIs in patients with viral infections and solid tumors Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Frontiers Apr 27, 2026
Meta-analysis of 55 studies assesses HCV prevalence trends across Eastern Mediterranean Region populations
Gastroenterology Meta-analysis
Meta-analysis of 55 studies assesses HCV prevalence trends across Eastern Mediterranean Region populations HCV Rates Drop in High-Risk Groups After 2015
This umbrella review synthesizes data from 55 meta-analyses evaluating hepatitis C virus (HCV) prevalence in the Eastern Mediterranean Regio…
Imagine walking into a doctor's office and feeling a knot of worry in your stomach.
Apr 22, 2026
Randomized trial shows ribavirin increases mutational load and specific transition signatures in HCV
Infectious Disease
Randomized trial shows ribavirin increases mutational load and specific transition signatures in HCV Ribavirin linked to increased hepatitis C virus mutations in trial
This secondary analysis of a randomized trial in HCV-infected participants found ribavirin exposure significantly increased total mutational…
Ribavirin treatment linked to increased hepatitis C virus mutations in a trial, though real-world impact on cure rates remains unclear.
medRxiv Apr 19, 2026
Meta-analysis of 9 studies estimates HCV seroprevalence of 3.63% among African refugees and displaced persons
Gastroenterology Meta-analysis
Meta-analysis of 9 studies estimates HCV seroprevalence of 3.63% among African refugees and displaced persons Hidden Virus Threats Among Displaced People
This systematic review and random-effects meta-analysis of 9 studies estimated hepatitis C virus (HCV) seroprevalence among refugees, asylum…
A new look at data shows hepatitis C is very common among refugees and displaced people in Africa, where they often face huge barriers to ge…
Apr 16, 2026
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan
Primary Care & Family Medicine Cohort
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan Can a computer predict your hepatitis C cure?
This retrospective cohort study evaluated machine learning prediction models in 221 comorbid HCV patients in Pakistan.
A new computer tool can spot which hepatitis C patients are likely to fail treatment before they even start taking pills.
Frontiers Apr 13, 2026
Global acute hepatitis C incidence declined overall but increased after 2015, analysis shows
Neurology Cohort
Global acute hepatitis C incidence declined overall but increased after 2015, analysis shows Is hepatitis C making a comeback? Global cases rose after 2015
An observational cohort analysis of global and Chinese populations from 1990 to 2021 found the global age-standardized incidence rate (ASIR)…
Global hepatitis C infections rose after 2015, reversing years of progress and creating a new public health challenge that experts must addr…
Frontiers Apr 4, 2026
CDC issues new guidance for completing hepatitis C virus testing
Gastroenterology
CDC issues new guidance for completing hepatitis C virus testing CDC updates guidance for completing hepatitis C testing to improve diagnosis
The CDC has published new guidance for completing hepatitis C virus testing.
The CDC released new guidance to help healthcare providers complete hepatitis C testing steps to confirm diagnoses.
CDC Apr 3, 2026

Research across Hepatitis

Related studies from across the Hepatitis family.

Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development
Rheumatology Meta-analysis
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development Elevated M2BPGi Levels Linked to Higher Risk of Liver Cancer
This systematic review and meta-analysis of 12,161 participants found that elevated serum M2BPGi is significantly associated with an increas…
A large review of over 12,000 patients found that high levels of a specific protein may signal an increased risk for liver cancer.
Frontiers Jul 19, 2026
Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc
Infectious Disease RCT
Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc Trial shows dolutegravir and lamivudine are safe for patients with HIV
This pooled analysis of Phase 3/3b trials evaluated dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B…
A review of multiple trials shows that a common two-drug regimen effectively manages HIV while remaining safe for those with hepatitis B ant…
Jul 18, 2026
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis
Hematology Meta-analysis
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis Case report: Brain infection in autoimmune hepatitis patient
This case report describes the management of disseminated nocardiosis in a 55-year-old man with autoimmune hepatitis. The patient showed gra…
A man with autoimmune hepatitis developed a rare brain infection after immunosuppression. Doctors treated it successfully with targeted anti…
Frontiers Jul 17, 2026
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors
Gastroenterology Meta-analysis
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors Specific Immune Inhibitors Show Varying Risks for Hepatitis B Reactivation
This meta-analysis of 29 studies evaluated the risk of hepatitis B virus reactivation (HBVr) in patients receiving various immunomodulators.…
New analysis shows that certain immune inhibitors like JAK inhibitors may carry a higher risk of hepatitis B reactivation than other drug cl…
Jul 1, 2026
HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk
Infectious Disease Sys. Review
HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk Clearing HBeAg helps manage chronic hepatitis B and liver risk
This systematic review examines the clinical significance and optimization strategies of HBeAg seroclearance in patients with HBeAg-positive…
Achieving HBeAg seroclearance in patients with chronic hepatitis B can lead to disease remission and a lower risk of developing liver cancer…
Frontiers Jun 29, 2026
Autoimmune hepatitis pathogenesis shifts from single molecule to immune-metabolic network analysis
Drug Pipeline Sys. Review
Autoimmune hepatitis pathogenesis shifts from single molecule to immune-metabolic network analysis New Research Maps Complex Networks in Autoimmune Hepatitis
This systematic review reframes autoimmune hepatitis (AIH) pathogenesis from a single-molecule perspective to a systematic regulatory networ…
Researchers are moving beyond single-molecule views to map complex immune and metabolic networks that drive autoimmune hepatitis.
Frontiers Jun 20, 2026
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Physical Medicine & Rehab Meta-analysis
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Jun 13, 2026
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B
Infectious Disease Sys. Review
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B Combination therapies may improve functional cure rates for chronic hepatitis B
This narrative review examines combining pegylated interferon-α with novel immunotherapies (antigen-reduction strategies, therapeutic vaccin…
A review suggests combining pegylated interferon with new immunotherapies could help achieve functional cure in chronic hepatitis B patients…
Frontiers Jun 6, 2026
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
Allergy & Immunology Sys. Review
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
Frontiers May 18, 2026
Meta-analysis identifies genetic variants linked to HBV susceptibility and HCC risk
Oncology Meta-analysis
Meta-analysis identifies genetic variants linked to HBV susceptibility and HCC risk Genetic Keys Unlock Why Some Get Liver Cancer From Hepatitis B
This meta-analysis of East Asian cohorts examined genetic variants associated with hepatitis B virus infection and hepatocellular carcinoma …
New research shows specific gene changes help explain why some people get Hepatitis B while others stay healthy.
May 2, 2026
Systematic review and meta-analysis of biopsy-guided versus clinically guided withdrawal in autoimmune hepatitis
Gastroenterology Meta-analysis
Systematic review and meta-analysis of biopsy-guided versus clinically guided withdrawal in autoimmune hepatitis Biopsy-guided withdrawal shows no benefit over clinical guidance for autoimmune hepatitis
This systematic review and meta-analysis evaluated relapse rates after treatment withdrawal in patients with autoimmune hepatitis.
A meta-analysis of 518 patients found that biopsy-guided withdrawal did not lower relapse rates compared to clinically guided withdrawal in …
May 1, 2026
HEV 239 vaccine induces durable humoral and cellular immunity in Bangladeshi women
Gastroenterology RCT
HEV 239 vaccine induces durable humoral and cellular immunity in Bangladeshi women Hepatitis E vaccine shows durable immunity in women
This longitudinal cohort study in 1480 women aged 16-39 years in Bangladesh found that HEV 239 (Hecolin) vaccination led to significantly hi…
A hepatitis E vaccine kept women protected for up to 3 years, with stronger immune memory than a comparison group.
May 1, 2026

Questions about Hepatitis C

How should healthcare workers follow up after an acute Hepatitis C Virus infection?

Healthcare workers with acute HCV should undergo baseline and serial HCV RNA testing, with follow-up for at least 6 months to confirm clearance or initiate treatment.

Full answer →
Why is the CDC recommending universal screening for Hepatitis C for pregnant women?

The CDC recommends universal Hepatitis C screening for all pregnant women because infection rates have doubled in the US since 2009, many cases go undiagnosed, and screening is now considered cost-effective.

Full answer →
Does taking ribavirin for Hepatitis C cause more genetic mutations in the virus?

Yes, ribavirin increases genetic mutations in HCV, as shown by a randomized trial that found higher mutational load and specific nucleotide changes in the virus.

Full answer →
How has the rate of Hepatitis C changed among younger adults in the US?

Hepatitis C rates have increased dramatically among younger US adults, driven by the opioid epidemic and injection drug use.

Full answer →

All Hepatitis C Articles